drugset / Trial / NCT00191633

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

NCT00191633

Phase 4 Completed 200 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess whether changes in the symptoms of ADHD show a relationship with changes in functioning in children with ADHD treated with atomoxetine over a 3-month period.

Timeline

Start
2005-04
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified